Delivery Order SPE2DB22D2005-SPE2DB25FJRY4
- Not listed
- The Defense Logistics Agency awarded a $367,720 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 0.4 mg/2 ml vials of glycopyrrolate. The single award delivery order was issued against an indefinite-delivery/indefinite-quantity contract vehicle and calls for the delivery of the pharmaceutical to a facility in Conshohocken, Pennsylvania by July 31, 2023. As a major distributor of medical supplies to the Department of Defense, Amerisourcebergen will fulfill this order to...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $22,402.51 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office division. The order is for the supply of 4559397622 - GLYCOPYRROLATE 0.2 MG/ML VIAL 20ML, a critical pharmaceutical product, with a completion date of December 16, 2022. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that Amerisourcebergen holds with DLA Troop Support Medical...
- This federal contract award, valued at $1,035.90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) designated as SPE2DX, which has a ceiling value of $999,999,999.00 and provides comprehensive global pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other government agencies through...
- The U.S. federal government, through the Defense Logistics Agency (DLA) Troop Support Medical, awarded a delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the supply of pharmaceuticals, specifically the drug glycopyrrolate 1 mg/5 ml vial 5 ml, with a ceiling value of $1,524.65. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,685.05, is for the delivery of glycopyrrolate 1 mg/5 ml vials. This is a firm fixed-price delivery order contract with a completion date of June 12, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 4565616879 - GLYCOPYRROLATE 0.2 MG/ML VIAL 5ML. The contract has an ultimate completion date of August 29, 2024 and a ceiling value of $15,536.46. The contract is not set aside. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that has been awarded numerous federal contracts to provide a wide range of medical commodities, including specialty...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,241.53 fixed-price contract is for the delivery of Glycopyrrolate 0.2 mg/ml vial, a medication used to treat certain conditions. The contract has a completion date of June 12, 2025 and is not set aside for any specific business category. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,047.22 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of GLYCOPYRROLATE INJECT, a medication, with a completion date of September 20, 2024. This delivery order is placed under a larger Indefinite Delivery Contract valued up to $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical, which provides a wide range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Glycopyrrolate 0.2 mg/ml vials (2 ml). The contract is a Firm Fixed Price Delivery Order with a ceiling value of $4,732.92 and an ultimate completion date of April 23, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,109.89 firm fixed-price delivery order is for the supply of GLYCOPYRROLATE 0.2 MG/ML VIALML, a medication. The contract has an ultimate completion date of May 9, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJRY4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,053.93 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Glycopyrrolate 0.2 mg/mL vials. This firm fixed-price, non-set-aside contract will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. The delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government. This award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a premier pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for military and veteran healthcare systems, supplying a comprehensive range of medications and medical supplies across multiple therapeutic areas. The company's competitively awarded contract portfolio with DLA demonstrates its capability to fulfill federal medical procurement requirements efficiently and reliably.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/18/25 |